Parkinson's Disease Biomarkers: Vital Tools for Neuroprotectants

Table of Contents

• Executive Summary
• Strategic Considerations
• Stakeholder Implications
• Introduction
• Shortcomings of Current Diagnosis
• Potential Role of Biomarkers
• The Pathophysiology of Parkinson' s Disease
• Background
• PD Pathophysiology and Use of Biomarkers
• The Value of a Biomarker for PD
• Pitfalls Facing Biochemical/Genetic Markers
• Biochemical Markers
• Genetic Markers
• Emerging Imaging Agents for PD Diagnosis
• GE Healthcare' s DaTSCAN
• Boston Life Sciences' Altropane
• MGI Pharmaceuticals' Dopascan
• Market Implications
• Concurrent Drug/Diagnostic Development: PD as a Blueprint for Neurological Indications
• Hurdles to Market
• Impact of PD Biomarkers on Neuroprotectant Development
• Outlook
• Bibliography

Tables

• 1. Parkinson' s Disease and Other Parkinsonian Disorders
• 2. Select Diagnostic Imaging Agents in Development, 2006
• 3. Strengths and Weaknesses of Current and Emerging Parkinson' s Disease Biomarkers
• 4. Select Biochemical and Genetic Biomarker Candidates in Parkinson' s Disease, 2006
• 5. Number of Total Prevalent Cases of Parkinson' s Disease in the Major Pharmaceutical Markets, 2005-2015
• 6. Development Status and Concurrent Drug Programs for Select Parkinson' s Disease Imaging Agents 2
• 7. Lundbeck/Teva' s Rasagiline: A Fact Sheet

Figures

• 1. Braak Staging of Parkinson' s Disease
• 2. Rate of Dopaminergic Neuron Loss over the Course of Parkinson' s Disease
• 3. Brain Structures Implicated in Movement and Parkinson' s Disease
• 4. Proposed Deficits in the Basal Ganglia Thalamocortical Circuit of Parkinson' s Disease Patients
• 5. SPECT Imaging Agent Targets at the Dopaminergic Synapse